Cephalon Hopes To Market Provigil With Anesta Actiq To Oncologists
Executive Summary
Cephalon hopes eventually to market the narcolepsy treatment Provigil to oncologists using the sales force that details Anesta's breakthrough cancer pain treatment Actiq, following a merger between the two companies.
You may also be interested in...
Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%
Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon
Cephalon Provigil Cost Of Goods To Decrease From 22% Of Sales To 7%
Cephalon expects to reduce its cost of goods associated with the narcolepsy drug Provigil from 22% of sales to 7% of sales following its acquisition of the French company Lafon
Ilex Resembles Recent Biotech Acquisition Targets As Campath Nears Market
Ilex Oncology appears to fit the profile of recently acquired companies within the biotechnology industry.